Asset Details
Do you wish to reserve the book?
Prazosin for the Treatment of Behavioral Symptoms in Patients With Alzheimer Disease With Agitation and Aggression
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Prazosin for the Treatment of Behavioral Symptoms in Patients With Alzheimer Disease With Agitation and Aggression
Do you wish to request the book?
Prazosin for the Treatment of Behavioral Symptoms in Patients With Alzheimer Disease With Agitation and Aggression
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Prazosin for the Treatment of Behavioral Symptoms in Patients With Alzheimer Disease With Agitation and Aggression
2009
Overview
Agitation/aggression in Alzheimer disease (AD) is a major cause of patient distress, caregiver burden, and institutionalization. Enhanced behavioral responsiveness to central nervous system norepinephrine (NE) release may contribute to the pathophysiology of agitation/aggression in AD. Prazosin, a nonsedating generic medication used for hypertension and benign prostatic hypertrophy, antagonizes NE effects at brain postsynaptic alpha-1 adrenoreceptors. This pilot study examined the efficacy and tolerability of prazosin for behavioral symptoms in patients with agitation/aggression in AD.
Double-blind, placebo controlled, parallel group study.
A university AD center and a nursing home in Seattle, WA.
Twenty-two nursing home and community-dwelling participants with agitation/aggression and probable or possible AD (mean age: 80.6 ± 11.2).
Randomization to placebo (N = 11) or prazosin (N = 11). Medication was initiated at 1 mg/day and increased up to 6 mg/day using a flexible dosing algorithm.
The Brief Psychiatric Rating Scale (BPRS) and Neuropsychiatric Inventory (NPI) at Weeks 1, 2, 4, 6, and 8. The Clinical Global Impression of Change (CGIC) at Week 8.
Participants taking prazosin (mean dose: 5.7 ± 0.9 mg/day) had greater improvements than those taking placebo (mean dose: 5.6 ± 1.2 mg/day) on the NPI (mean change: −19 ± 21 versus −2 ± 15, χ2 = 6.32, df = 1, p = 0.012) and BPRS (mean change: −9 ± 9 versus −3 ± 5, χ2 = 4.42, df = 1, p = 0.036) based on linear mixed effects models and the CGIC (mean: 2.6 ± 1.0 versus 4.5 ± 1.6, z = 2.57, p = 0.011 [Mann-Whitney test]). Adverse effects and blood pressure changes were similar between prazosin and placebo groups.
Prazosin was well tolerated and improved behavioral symptoms in patients with agitation/aggression in AD.
Publisher
Elsevier Inc,Elsevier Limited
Subject
Adrenergic alpha-Antagonists - therapeutic use
/ Aged
/ Alzheimer Disease - diagnosis
/ Alzheimer Disease - drug therapy
/ Alzheimer Disease - physiopathology
/ Alzheimer Disease - psychology
/ Behavior
/ Behavioral Symptoms - drug therapy
/ Brain
/ Brief Psychiatric Rating Scale
/ Changes
/ dementia
/ Disease
/ Dosage
/ Drug Administration Schedule
/ Drugs
/ Efficacy
/ Female
/ Humans
/ Male
/ Measures
/ Patients
/ prazosin
/ Psychomotor Agitation - drug therapy
/ Psychomotor Agitation - psychology
/ Symptoms
